S-1/A: Aptevo Therapeutics Seeks $17.5 Million in Public Offering to Advance Cancer Immunotherapy Pipeline

Aptevo Therapeutics launches a public offering of common stock and warrants to raise capital for clinical programs and general corporate purposes.

Summary

• Aptevo Therapeutics Inc. is undertaking a public offering to sell up to 15,086,207 shares of common stock, along with Series A and Series B warrants.
• The offering also includes pre-funded warrants for purchasers who would exceed ownership limits, exercisable for one share of common stock at $0.0001 per share.
• Each share of common stock or pre-funded warrant is offered with one Series A warrant and one Series B warrant.
• The Series A warrants are exercisable five years after stockholder approval, while Series B warrants expire in two and a half years post-approval.
• The Series B warrants include a 'zero exercise price' option, potentially leading to the issuance of up to 407,327,586 shares of common stock.
• The company intends to use the net proceeds, estimated at $16.0 million, for working capital, clinical programs, and general corporate purposes.
• Roth Capital Partners, LLC is acting as the exclusive placement agent for the offering, which will terminate no later than May 15, 2025.
• Concurrently with the offering, Aptevo plans a private placement of Series C and Series D warrants to existing warrant holders as consideration for waiving certain restrictions, potentially issuing up to 46,118,464 shares of common stock upon exercise.

Sentiment

Score: 5

Explanation: The document is neutral in tone, primarily outlining the terms of the public offering. The potential for dilution and the speculative nature of the warrants temper any positive sentiment.

Positives

• The offering aims to provide Aptevo with additional capital to advance its clinical programs and support general corporate activities.
• The 'zero exercise price' option on the Series B warrants could incentivize warrant holders to exercise, potentially increasing the number of outstanding shares and liquidity.
• The concurrent private placement provides additional consideration to existing warrant holders, potentially strengthening relationships with key investors.

Negatives

• The 'zero exercise price' option on the Series B warrants could lead to substantial dilution for existing stockholders.
• There is no guarantee that the company will receive any cash proceeds from the exercise of the Series B Warrants.
• The offering is a 'reasonable best efforts' offering, meaning there is no guarantee that all securities will be sold, potentially reducing the amount of capital raised.
• The company has broad discretion in the use of the net proceeds from this offering and may not use them effectively.

Risks

• The company may not raise the amount of capital it believes is required for its business plans.
• The market price of the common stock could decline due to the offering.
• The common stock may be at risk for delisting from the Nasdaq Capital Market if the company does not maintain compliance with Nasdaq's continued listing requirements.
• The common warrants and pre-funded warrants are speculative in nature.
• The Series A Warrants and the Series B Warrants are not exercisable until Stockholder Approval and may not have any value.
• The Securities Purchase Agreement that the company is entering into in connection with this offering does not contain a prohibition against short sales between the time of closing this offering and obtaining Stockholder Approval which may drive down the market price of the common stock ahead of obtaining Stockholder Approval.

Future Outlook

Aptevo intends to use the net proceeds from this offering for working capital to fund its clinical programs and general corporate purposes, including the further development of its product candidates.

Industry Context

Bispecific therapeutics are increasingly recognized as potent anti-cancer agents. Sixteen new bispecific agents have been approved for use by the FDA in the last three years and there is a total of 125 bispecific drug candidates currently in development.

Stakeholder Impact

• Existing stockholders may experience dilution due to the issuance of new shares.
• New investors will have an immediate dilution in net tangible book value.
• The company's ability to fund its clinical programs and operations will be enhanced.
• The offering could impact the market price of the company's common stock.

Next Steps

• Seek Stockholder Approval for the issuance of shares upon exercise of the common warrants.
• Close the public offering by May 15, 2025.
• Issue Series C and Series D warrants in a concurrent private placement.
• Utilize net proceeds for clinical programs and general corporate purposes.

Key Dates

Keywords

public offering, common stock, warrants, Aptevo Therapeutics, clinical programs, Series A warrants, Series B warrants, pre-funded warrants, Roth Capital Partners, capital raise, biotechnology, immunotherapy, cancer